Management of Osteitis Pubis with Erosive Changes in a 65-Year-Old
For osteitis pubis with erosive changes in a 65-year-old patient, first-line treatment should begin with NSAIDs/COXIBs at maximum tolerated dosage, followed by intravenous bisphosphonates or TNF inhibitors if initial treatment fails, with treatment decisions guided by clinical symptoms and radiological evidence of inflammation. 1
Diagnostic Workup
Imaging studies:
Laboratory tests:
Consider bone biopsy only if there is suspicion of malignancy or infectious osteomyelitis 1
Disease Activity Assessment
Categorize the patient based on clinical symptoms and radiological findings 2:
- Active CNO: Corresponding clinical symptoms (pain) AND radiological disease activity (bone marrow edema/increased tracer uptake) - initiate treatment
- Inactive CNO: Neither clinical symptoms nor radiological disease activity - no treatment needed
- Probable inactive CNO: Clinical symptoms WITHOUT radiological disease activity - investigate other causes of pain
- No clinically relevant CNO activity: Radiological disease activity WITHOUT clinical symptoms - consider treatment in shared decision
Treatment Algorithm
First-Line Treatment 2, 1
- NSAIDs/COXIBs at maximum tolerated dosage:
- Options include naproxen, indomethacin, ibuprofen, celecoxib, etoricoxib, piroxicam, or meloxicam
- Evaluate response at 2-4 weeks
- If sufficient response: continue and re-evaluate at 12 weeks
- If insufficient response: consider NSAID rotation or advance to second-line treatment
Adjunctive First-Line Options 2, 1
- Patient education and lifestyle modifications
- Physical therapy to maintain mobility and strength
- Consider short courses of oral prednisolone (e.g., 20mg daily for 5-7 days) as bridging therapy
- Consider local glucocorticoid injections for focal pain
Second-Line Treatment 2, 1
If NSAIDs/COXIBs fail after 2-4 weeks:
- Intravenous bisphosphonates (first choice):
- Pamidronate: 60mg IV every 3 months
- Zoledronate: 5mg IV once yearly
- Evaluate response at 3-6 months
OR
- TNF inhibitors:
- Options include infliximab, etanercept, adalimumab, golimumab, or certolizumab
- Evaluate response at 3-6 months
If sufficient response: continue and re-evaluate at 6-12 months If insufficient response: switch to the alternative second-line treatment or consider combination therapy
Third-Line Treatment 2
- Refer to specialized center for additional treatment options if both second-line treatments fail
Special Considerations for Elderly Patients
- In the 65-year-old population, carefully monitor for NSAID-related adverse effects (GI, renal, cardiovascular)
- Consider gastroprotection with proton pump inhibitors when using NSAIDs
- Assess bone mineral density before initiating bisphosphonates
- Monitor for bisphosphonate-related adverse effects including hypocalcemia and osteonecrosis of the jaw
Surgical Management
- Surgery is rarely required for non-athletic patients with osteitis pubis 3
- Consider surgical intervention only when all conservative measures have failed and pain remains disabling 4
- Surgical options may include:
Treatment Response Evaluation
- Assess treatment response primarily based on clinical measures (pain reduction, improved function) 2, 1
- Integrate radiological measures (reduction in bone marrow edema or tracer uptake) 2
- Consider biochemical measures if previously elevated 1
Prognosis
- Most non-athletic patients with osteitis pubis respond well to conservative treatment 3
- With proper diagnosis and treatment, prognosis for recovery is generally excellent 1
- Patients should be monitored for potential complications such as progressive structural damage or functional limitations 2
Common Pitfalls to Avoid
- Failing to rule out infectious causes before diagnosing chronic non-bacterial osteitis
- Relying solely on MRI findings for treatment decisions, as abnormal findings can be present in asymptomatic individuals 5
- Premature advancement to surgical intervention before exhausting conservative options
- Inadequate duration of first-line therapy before moving to second-line options